Return on investment in needle and syringe programs in Australia: report

4 Financial effects of NSPs

Page last updated: 2002

An economic model was developed that compares the costs of operating NSPs during the 1990s to the anticipated savings that will accrue from the number of cases of HIV and HCV avoided as a result of NSPs. This section describes the data sources and methodology used in the financial analysis.

4.1 Description of the economic model

4.2 Expenditure of NSPs

4.3 Impacts of NSPs on HIV and HCV

4.4 Methodology for health care costings for HIV

4.5 Methodology for health care costings for HCV infection

4.6 HIV treatment costs

4.7 Return on investment

4.8 Sensitivity analysis

4.9 Discussion